Cogent Biosciences Q3 net loss widens on higher expenses

Overview

• U.S. biotech firm reported Q3 net loss widened to $111.4 mln as expenses rose

• Company's R&D and G&A expenses increased due to clinical trials and commercial launch readiness

• Cash balance of $791.1 mln expected to fund operations into late 2028

Outlook

• Company expects potential FDA approval of bezuclastinib in GIST by Nov. 30, 2026

• Potential FDA approval of bezuclastinib in NonAdvSM expected by Dec. 30, 2026

• Potential FDA approval of bezuclastinib in AdvSM expected by June 29, 2027

Result Drivers

• R&D SPENDING - Higher research and development expenses driven by ongoing SUMMIT, PEAK and APEX clinical trials and early-stage pipeline programs

• COMMERCIAL READINESS - Increased general and administrative costs attributed to investments in commercial readiness and organizational growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Cogent Biosciences, Inc. is $55.00, about 74.7% above its November 4 closing price of $31.49

Reuters Recommended Reads

• Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

• Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)